TRIM59 was proven to enhance PC progression by activating the PI3K/AKT/mTOR-glycolysis signaling pathway [61], CRC [203], breast cancer [88], and cholangiocarcinoma progression [192]. This evidence concerns the gene AKT1 and breast carcinoma.